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as well as creatinine, cystatin C, blood NGAL, urinary NGAL and electrolytes
was also obtained. AKI was defined by an increase in creatinine ≥ 0.3mg/l rel-
ative to the admission level. Exclusion criteria was eGFR < 15ml/min/1.73m²
and atrial fibrillation. 
Results: among the 26 included patients, AKI occurred in 8 patients at day
3 and in 10 patients at discharge. Mean RRI values were 0.71±0.08 on admis-
sion, 0.71±0.09 at day 3 and 0.74±0.08 at discharge. RRI was related to age,
creatinine and cystatin C (p≤0.05 for all) but not to other clinical or echocar-
diographic variables or BNP or NGAL levels. Only admission RRI was
significantly associated with AKI at day 3 (table) as well as RRI at day 3 for
AKI at discharge (0.77±0.07 vs 0.67±0.8; p=0.02). 
Conclusion: this pilot study describes RRI values as well as its early
changes and determinants during AHF. Doppler-derived RRI measurement
appears to be a relevant tool for predicting AKI.
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Background: Right ventricle failure (RVF) is a frequent and severe
complication after cardiac transplantation. However, risk stratification for
RVF is poorly achieved. Development of transcriptomic biomarkers for out-
come prediction in cardio-vascular diseases is promising. 
Aim: To identify right ventricular gene expression signature associated to
RVF and to define a transcriptomic biomarker that could predict post-trans-
plantation RVF. 
Methods: Recipient RV myocardial samples of 44 patients transplanted
from February 1998 to November 2002 in our center were collected. We ret-
rospectively identified patients with (RVF group) and without (CTL group)
post-transplantation RVF. 
A 4035-gene expression profile was obtained for all patients. Differentially
expressed genes between RVF and CTL groups were identified and a mole-
cular RVF predictor was used to determine for each patient a RVF prediction
score (RVFs). 
Results: 9 (20%) and 18 (41%) patients were classified in RVF and CTL
groups respectively. As compared to CTL group, RVF patients showed higher
pre-operative bilirubin level and higher post-operative death rate. Molecular
RVF predictor included 75 differentially expressed genes. Using this predictor,
risk for post-transplantation RVF was 2.8-fold greater if RVFs was >0.5 (CI
95%: 1.243-6.305). Sensitivity and specificity of RVFs were 0.778 and 0.889,
respectively. Using receiver operating characteristic analysis, RVFs area under
curve (AUC) was significantly greater than AUC of commonly used RVF pre-
dictors (pulmonary vascular resistance, trans-pulmonary gradient). 
Conclusion: Gene expression profiling of recipient right ventricle could be
used to predict post-transplantation RVF. Transcriptomic biomarkers should be
further investigated as a new tool for selection of cardiac transplant candidates. 
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With the shortage of grafts, mechanical circulatory support has emerged as
an alternative to heart transplantation. This activity requires a multidisci-
plinary team specialized in the treatment of heart failure.
This is a single-center prospective cohort of patients under long-term intra-
corporeal and continuous-flow left assist device type HeartMate II, between
january 2008 and january 2014.
Thirty-four devices were implanted in 30 men (88.2%) and 4 women
(11.8%) with a mean age of 57.8 years. It concerned ischemic cardiomyopathy
in 25 cases (73.5%) and primitive dilation in 9 cases (26.5%). The objective was
a « destination therapy » in 11 patients (32.4%) and a « bridge-to-transplant » in
23 patients (67.6%). The 30-day mortality was 4 cases (11.8%), there were
11 deaths (32.4%) with a 1-year survival of 89.5%. Right ventricular failure,
defined by a use of inhaled nitrogen monoxide > 48 hours and/or inotropes
>14 days, appeared in 14 cases (41.2%). Associated factors were: young age,
high pulmonary arterial resistances and right pressures, increased bilirubin and
cavitary dilation. The mean duration of intubation was 5 days and ICU stay of
13.2 days. Initial suites were marked by 6 surgical re-openings for bleeding
(17.6%), 5 acute renal failures requiring dialysis (14.7%) and 10 acute respira-
tory distresses (29.4%). Follow-up was performed in a dedicated unit, with func-
tional, ultrasound and rythmological assessment, dietary and psycho-social
support, and finally therapeutic education. The main late complications included
4 strokes (11.8%), ischemic or haemorragic, and 9 driveline infections (26.5%).
Two patients were transplanted, two others are on waiting list.
Thanks to close collaboration between cardiologists and surgeons, the man-
agement of patients with en-stage heart failure has improved with our growing
experience in the field of long-term assistance.
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With the shortage of grafts, mechanical circulatory support has emerged as
an alternative to heart transplantation. But one of the main disadvantages is
the percutaneous source of energy that exposes to the risk of infection.
We studied driveline infections occurred in a single-center prospective
cohort of patients with long-term intracorporeal and continuous-flow left assist
device type HeartMate II, between January 2008 and January 2014.
Among the 34 devices implanted, we identified 9 cases of infection of the
power cable (26.5%). The diagnosis was defined by the combination of a pos-
itive bacteriological sample with local inflammatory signs, ranging from skin
redness to frank pus. The germs found included: 5 aureus staphylococci,
3 white staphylococci, 3 gram-negative bacilli including a pseudomonas aeru-
ginosa, and a citrobacter. The median time to onset of infection was
15 months, ranging from 3 weeks to 2.5 years after implantation. Associated
factors were: surgical re-opening, prolonged ICU stay, acute renal failure, the
existence of a concomitant infection, malnutrition, duration of assistance and
dressing changes at home. The treatment was based on a broad-spectrum anti-
biotics, secondarily adapted to the antibiogram and long lasting. Among these
patients, two were transplanted, including one in the context of a Type 2 Super
Emergency, two others died of a non-infectious cause, one patient is now
cured and four are still carrying a chronic related-device infection.
The management of end-stage heart failure has improved thanks to our
growing experience in the field of long-term assistance, but the driveline
infection is a major complication. It greatly affects the quality of life of the
patients and transplantation may be the only prospect of recovery. 
Abstract 0163 – Table
Admission variables No AKI AKI p 
Age 60±17 69±14 0.29
LVEF 25±8 33±17 0.78
Blood Pressure 122±18 118±19 0.63
eGFR 62±24 52±20 0.35
Cystacin C 1.4±0.6 1.8±0.7 0.08
NGAL blood 125±84 147±130 0.76
NGAL urinary 13±17 9±4 0.79
BNP 1979±1815 1562±881 0.95
IRR 0.68±0.08 0.76±0.06 0.03
